...
首页> 外文期刊>Clinical kidney journal >Rescue therapy with eculizumab in a transplant recipient with atypical haemolytic-uraemic syndrome
【24h】

Rescue therapy with eculizumab in a transplant recipient with atypical haemolytic-uraemic syndrome

机译:依库丽单抗对非典型溶血尿毒症综合征移植患者的抢救治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Haemolytic-uraemic syndrome is a clinical syndrome characterized by thrombocytopaenia, non-autoimmune haemolytic anaemia and renal impairment. Pathological alterations in kidney samples show thrombotic microangiopathy. The underlying pathogenesis is endothelial cell injury with throm-botic occlusion of the arterioles and capillaries. A variety of causes have been identified, associated with infection of Escherichia coll O157:H7, environmental factors as immunosuppressive drugs and genetic deficiencies in complement regulatory factors. The latter is called atypical haemolytic-uraemic syndrome (aHUS). Here, we present a patient with severe aHUS with complement factor H deficiency triggered by cocaine use and recurrence after kidney transplantation. The patient restarted haemo-dialysis for severe renal insufficiency and anti-C5 antibody eculizumab was used as salvage treatment with progressive recovery of graft function and suppression of dialysis.
机译:溶血尿毒综合征是一种以血小板减少症,非自身免疫性溶血性贫血和肾功能不全为特征的临床综合征。肾脏样本中的病理改变显示出血栓性微血管病。潜在的发病机制是内皮细胞损伤,小动脉和毛细血管栓塞形成血栓。已鉴定出多种原因,与大肠杆菌Coll O157:H7的感染,作为免疫抑制药的环境因素以及补体调节因子的遗传缺陷有关。后者称为非典型溶血尿毒综合症(aHUS)。在这里,我们介绍了一名严重的aHUS患者,其可卡因的使用触发了补体因子H缺乏症,并且在肾移植后复发。该患者因严重肾功能不全而开始血液透析,抗C5抗体依库丽单抗用作挽救性治疗,可逐步恢复移植物功能并抑制透析。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号